Objective: The aim of present study is to develop and explore efficiency of
5.0G EDA PAMAM dendrimers as long-duration drug release carriers for the treatment
Method: Rifampicin (RIF) was selected as a major drug for incorporation into PAMAM
dendrimers based on its anti-tubercular activity and hydrophobic nature. Further polyethylene
glycol (PEGylated) PAMAM dendrimers were evaluated for their hemolytic toxicity
and in vivo anti-tubercular studies. The 5.0G PAMAM dendrimers are prepared by
using initiator core ethylene diamine and methyl acrylate. Furthermore, the PEGylation
was done by polyethylene glycol 2000 using epichlorhydrin as a cross linking agent.
Result: The Rifampicin loaded PEGylated 5.0G PAMAM dendrimers were characterized
by FTIR, NMR, DSC and SEM analysis. The in vivo study report ensures the suitability
of PEGylated dendrimer in connection to prolonged delivery of Rifampicin. Moreover,
PEGylated system has shown a reduced hemolytic toxicity.
Conclusion: The observed results concluded that the PEGylated method was less time
consuming, inexpensive, and reproducible, and it also reduces toxicity.